Lights, fluorescence, action—Influencing wound treatment plans including debridement of bacteria and biofilms
Ashley Jacob1, Laura M. Jones1, Raymond J. Abdo2, Sebastian F. Cruz-Schiavone3, Robert Skerker4, Wayne J. Caputo5, Nathan Krehbiel1, Audrey K. Moyer-Harris1, Alyssa McAtee6, Isabel Baker1, Micaela D. Gray1, Monique Y. Rennie1
1MolecuLight Inc., Toronto, Ontario, Canada 2St. Louis Foot & Ankle, St. Louis, Missouri, USA 3Adamant Medical Group, Pittsburgh, Pennsylvania, USA 4Atlantic Health, Morristown, New Jersey, USA 5Clara Maass Medical Center, Belleville, New Jersey, USA 6Agiliti Health, Inc., Minneapolis, Minnesota, USA
Int Wound J. 2023;1–10.
Related Publications

Detection of Bacterial Burden

Anti-Microbial Stewardship

Detection of Bacterial Burden

Detection of Bacterial Burden


Detection of Bacterial Burden
MolecuLight Headquarters
425 University Avenue
Suite 700
Toronto, ON M5G 1T6
Canada
US Address
MolecuLight Corp.
2403 Sidney Street,
Suite 209
Pittsburgh, PA 15203
T. +1 647-362-4684
North American Toll Free:
1-877-818-4360
F.+1 647-362-4730
E: info@moleculight.com
©2023
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.